Rapidly and efficiently releases glutamate (Cat. No. 0218) when photolysed (350 - 365 nm excitation). Water soluble and stable at neutral pH, and pharmacologically inactive at neuronal glutamate receptors (up to 200 μM). 5.5 times more photosensitive than MNI-caged L-glutamate (Cat. No. 1490). Laser activation of MDNI-glu evokes a rapid increase in intracellular Ca2+ concentration in astrocytes.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||3.68||10mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 368.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.72 mL||13.58 mL||27.15 mL|
|5 mM||0.54 mL||2.72 mL||5.43 mL|
|10 mM||0.27 mL||1.36 mL||2.72 mL|
|50 mM||0.05 mL||0.27 mL||0.54 mL|
References are publications that support the products' biological activity.
Fedoryak et al (2005) Synthesis of a caged glutamate for efficient one- and two-photon photorelease on living cells. Chem. Commun. (Camb.) 7 3664 PMID: 16027904
Papageorgiou et al (2005) Synthetic and photochemical studies of substituted 1-acyl-7-nitroindolines. Photochem.Photobiol.Sci. 4 887 PMID: 16252044
Popovic et al (2015) Electrical behaviour of dendritic spines as revealed by voltage imaging. Nat.Commun. 6 8436 PMID: 26436431
If you know of a relevant reference for MDNI-caged-L-glutamate, please let us know.
View Related Products by Target
Keywords: MDNI-caged-L-glutamate, supplier, Stable, photoreleaser, L-glutamate, Caged, Compounds, Glutamate, mGlur, Receptors, Metabotropic, Non-Selective, iGlur, Ionotropic, agonists, MNI, glutamate, MNI-Glutamate, caged, MDNI, glutamate, DNI, glutamate, DNI-GLU, Miscellaneous, Glutamate, Non-selective, Ionotropic, Glutamate, Non-selective, mGlu, Caged, Glutamate, Compounds, Miscellaneous, Glutamate, Tocris Bioscience
Citations for MDNI-caged-L-glutamate
Citations are publications that use Tocris products.
Currently there are no citations for MDNI-caged-L-glutamate. Do you know of a great paper that uses MDNI-caged-L-glutamate from Tocris? If so please let us know.
Reviews for MDNI-caged-L-glutamate
There are currently no reviews for this product. Be the first to review MDNI-caged-L-glutamate and earn rewards!
Have you used MDNI-caged-L-glutamate?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.